FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980174578> ?p ?o ?g. }

• W2980174578 abstract "Abstract Abstract 3603 The mammalian mitochondrial caseinolytic protease (mClpP) is a nuclear-encoded enzyme complex responsible for degrading excess proteins in the mitochondria. It is functionally similar to the proteasome complex in the cytoplasm and structurally homologous to the bacterial ClpP enzyme complex. While the proteasome has been well characterized as a therapeutic target for the treatment of hematologic malignancy, little is known regarding mClpP as a potential therapeutic target in malignant cells. Therefore, we evaluated the expression of mClpP in acute myeloid leukemia (AML) and normal hematopoietic cells by immunoblotting. Strikingly, mClpP was robustly expressed in AML cell lines (n=3/4) and primary AML patients (n=4/4), but was undetectable in normal bone marrow samples (n = 3) and G-CSF-mobilized peripheral blood mononuclear cells from consenting volunteers donating stem cells for allotransplant (n = 5). We also demonstrated over-expression of mClpP mRNA in these AML samples compared to normal by Q-RT-PCR. Next, we knocked down mClpP and its regulatory chaperone protein mClpX in OCI-AML2 and TEX human leukemia cells using 3 independent shRNA in lentiviral vectors. Target knockdown was confirmed by Q-RT-PCR and immunoblotting. Compared to cells infected with control sequences, knockdown of mClpP reduced the growth and viability of these leukemia cells by > 90%. Knockdown of the chaperone protein mClpX also reduced the growth and viability of these cells, but with less potency than mClpP knockdown. Rho-zero cells have been depleted of mitochondrial DNA by treatment with ethidium bromide and therefore lack mitochondrial protein synthesis. Through feedback mechanisms, expression of nuclear encoded proteins that contribute to oxidative metabolism are also reduced. Thus, these cells have lower rates of mitochondrial protein accumulation and turnover. We demonstrated that wild type and rho-zero 143B rhabdomyosarcoma cells both express mClpP protein, but levels were slightly lower in the rho-zero cells. We then tested the effects of mClpP knockdown in rho-zero cells and demonstrated that knockdown of mClpP reduced the growth and viability of wild type 143B cells, but had little effect on their rho-zero counterparts. As a chemical approach to evaluate the effects of mClpP inhibition on AML and normal hematopoietic cells, we synthesized a derivative of recently reported beta-lactone bacterial ClpP inhibitor and generated (3RS,4RS)-3-(non-8-en-1-yl)-4-(2-(pyridin-3-yl)ethyl)oxetan-2-one that we termed A2–32–01. We confirmed that A2–32–01 inhibited the enzymatic activity of recombinant bacterial ClpP similar to the activity of the reported beta-lactone inhibitors. A2–32–01 induced cell death in TEX, OCI-AML2, and K562 leukemia cells that express mClpP as measured by trypan blue staining. We also isolated mitochondria from these cells after treatment with A2–32–01 and demonstrated that the compound reduced the enzymatic activity of the mClpP protease as measured by cleavage of the fluorogenic substance N-succinyl-Leu-Tyr-7-amidomethylcoumarin (Suc-LY-AMC). In contrast, A2–32–01 was not cytotoxic to HL60 cells that had undetectable mClpP. Likewise, A2–32–01 induced death in 143B wild type cells, but not the rho-zero counterparts. Finally, we evaluated the effects of mClpP inhibition on primary AML and normal hematopoietic cells. Primary AML and normal hematopoietic cells were treated with increasing concentrations of A2–32–01 and cell viability was measured after 48 hours incubation by Annexin V/PI staining followed by flow cytometry. A2–32–01 did not kill normal hematopoietic cells (n = 3 samples), but was cytotoxic to 5/6 tested primary AML cells. In summary, we have used genetic and chemical approaches to highlight the mitochondrial protease, mClpP, as a novel therapeutic target for AML. Disclosures: No relevant conflicts of interest to declare." @default.
• W2980174578 created "2019-10-18" @default.
• W2980174578 creator A5002804852 @default.
• W2980174578 creator A5026588093 @default.
• W2980174578 creator A5028072253 @default.
• W2980174578 creator A5028232586 @default.
• W2980174578 creator A5033311841 @default.
• W2980174578 creator A5039379710 @default.
• W2980174578 creator A5045250493 @default.
• W2980174578 creator A5069066501 @default.
• W2980174578 creator A5073300511 @default.
• W2980174578 creator A5077991160 @default.
• W2980174578 creator A5078965986 @default.
• W2980174578 creator A5083765234 @default.
• W2980174578 creator A5089090191 @default.
• W2980174578 date "2012-11-16" @default.
• W2980174578 modified "2023-09-28" @default.
• W2980174578 title "Targeting the Mammalian Mitochondrial Clpp (mClpP) As a Novel Therapeutic Strategy for Acute Myeloid Leukemia" @default.
• W2980174578 doi "https://doi.org/10.1182/blood.v120.21.3603.3603" @default.
• W2980174578 hasPublicationYear "2012" @default.
• W2980174578 type Work @default.
• W2980174578 sameAs 2980174578 @default.
• W2980174578 citedByCount "0" @default.
• W2980174578 crossrefType "journal-article" @default.
• W2980174578 hasAuthorship W2980174578A5002804852 @default.
• W2980174578 hasAuthorship W2980174578A5026588093 @default.
• W2980174578 hasAuthorship W2980174578A5028072253 @default.
• W2980174578 hasAuthorship W2980174578A5028232586 @default.
• W2980174578 hasAuthorship W2980174578A5033311841 @default.
• W2980174578 hasAuthorship W2980174578A5039379710 @default.
• W2980174578 hasAuthorship W2980174578A5045250493 @default.
• W2980174578 hasAuthorship W2980174578A5069066501 @default.
• W2980174578 hasAuthorship W2980174578A5073300511 @default.
• W2980174578 hasAuthorship W2980174578A5077991160 @default.
• W2980174578 hasAuthorship W2980174578A5078965986 @default.
• W2980174578 hasAuthorship W2980174578A5083765234 @default.
• W2980174578 hasAuthorship W2980174578A5089090191 @default.
• W2980174578 hasConcept C109159458 @default.
• W2980174578 hasConcept C142724271 @default.
• W2980174578 hasConcept C1491633281 @default.
• W2980174578 hasConcept C153911025 @default.
• W2980174578 hasConcept C173396325 @default.
• W2980174578 hasConcept C190283241 @default.
• W2980174578 hasConcept C203014093 @default.
• W2980174578 hasConcept C2775962898 @default.
• W2980174578 hasConcept C2778461978 @default.
• W2980174578 hasConcept C2778729363 @default.
• W2980174578 hasConcept C28328180 @default.
• W2980174578 hasConcept C502942594 @default.
• W2980174578 hasConcept C53227056 @default.
• W2980174578 hasConcept C55493867 @default.
• W2980174578 hasConcept C71924100 @default.
• W2980174578 hasConcept C86803240 @default.
• W2980174578 hasConcept C95444343 @default.
• W2980174578 hasConceptScore W2980174578C109159458 @default.
• W2980174578 hasConceptScore W2980174578C142724271 @default.
• W2980174578 hasConceptScore W2980174578C1491633281 @default.
• W2980174578 hasConceptScore W2980174578C153911025 @default.
• W2980174578 hasConceptScore W2980174578C173396325 @default.
• W2980174578 hasConceptScore W2980174578C190283241 @default.
• W2980174578 hasConceptScore W2980174578C203014093 @default.
• W2980174578 hasConceptScore W2980174578C2775962898 @default.
• W2980174578 hasConceptScore W2980174578C2778461978 @default.
• W2980174578 hasConceptScore W2980174578C2778729363 @default.
• W2980174578 hasConceptScore W2980174578C28328180 @default.
• W2980174578 hasConceptScore W2980174578C502942594 @default.
• W2980174578 hasConceptScore W2980174578C53227056 @default.
• W2980174578 hasConceptScore W2980174578C55493867 @default.
• W2980174578 hasConceptScore W2980174578C71924100 @default.
• W2980174578 hasConceptScore W2980174578C86803240 @default.
• W2980174578 hasConceptScore W2980174578C95444343 @default.
• W2980174578 hasLocation W29801745781 @default.
• W2980174578 hasOpenAccess W2980174578 @default.
• W2980174578 hasPrimaryLocation W29801745781 @default.
• W2980174578 hasRelatedWork W162742369 @default.
• W2980174578 hasRelatedWork W1974311347 @default.
• W2980174578 hasRelatedWork W2008002281 @default.
• W2980174578 hasRelatedWork W2022579249 @default.
• W2980174578 hasRelatedWork W2124935569 @default.
• W2980174578 hasRelatedWork W2141272173 @default.
• W2980174578 hasRelatedWork W2163676100 @default.
• W2980174578 hasRelatedWork W2340502986 @default.
• W2980174578 hasRelatedWork W2416717377 @default.
• W2980174578 hasRelatedWork W2546036185 @default.
• W2980174578 hasRelatedWork W2558870161 @default.
• W2980174578 hasRelatedWork W2575351375 @default.
• W2980174578 hasRelatedWork W2588380004 @default.
• W2980174578 hasRelatedWork W2588938386 @default.
• W2980174578 hasRelatedWork W2591524699 @default.
• W2980174578 hasRelatedWork W2910464231 @default.
• W2980174578 hasRelatedWork W2932582546 @default.
• W2980174578 hasRelatedWork W2980260437 @default.
• W2980174578 hasRelatedWork W3016744120 @default.
• W2980174578 hasRelatedWork W3167895848 @default.
• W2980174578 isParatext "false" @default.
• W2980174578 isRetracted "false" @default.
• W2980174578 magId "2980174578" @default.
• W2980174578 workType "article" @default.